Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib vs placebo in indolent or smouldering systemic mastocytosis with severe handicap
2024-514538-19-00Phase 3Completed
- Sponsor
- AB Science
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in indolent systemic mastocytosis (ISM) and systemic mastocytosis (SM) comparing Masitinib with Placebo (2 arms). Primary endpoint: Primary cumulative response on handicaps from week 8 to week 24. Started Jan 2025; status: completed.
02
Drugs
masitinib
03
Conditions
indolent systemic mastocytosis (ISM)systemic mastocytosis (SM)
Beyond the preview
Go deeper on 2024-514538-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514538-19-00.